Trial reportJournal of neurology2010
Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study.
Trial report in Journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Pooled it
- Pooled it
- Guideline
- Trial
- An Exploratory Randomized Controlled Trial of a 12-Week Yoga Versus Educational Film Program for the Management of Restless Legs Syndrome: Feasibility and Acceptability.Journal of integrative and complementary medicine · 2022Trial
- Sleep Related Movement Disorders: What's New and Changing Clinical Practice.Journal of sleep research · 2025Review
- Hydrotherapy and acupressure for restless legs syndrome: results of a qualitative part of a randomized controlled exploratory study.Frontiers in medicine · 2025Article
- Hydrotherapy and acupressure in restless legs syndrome: results of a randomized, controlled, three-armed, pilot study (HYDRAC-study).Frontiers in medicine · 2025Article
- Article
- Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China.Sleep & breathing = Schlaf & Atmung · 2022Observational
- [Sleep medicine in psychiatry and psychotherapy].Der Nervenarzt · 2022Article
- Restless Legs Syndrome Prevalence and Clinical Correlates Among Psychiatric Inpatients: A Multicenter Study.Frontiers in psychiatry · 2022Article
- [Update on restless legs syndrome].Der Nervenarzt · 2020Article
- Article
- Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Observational
- Sleep in Parkinson's Disease with Impulse Control Disorder.Current neurology and neuroscience reports · 2018Review
- Review
- Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management.Frontiers in aging neuroscience · 2017Review
- Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED).Current treatment options in neurology · 2016Article
- Restless legs syndrome-current therapies and management of augmentation.Nature reviews. Neurology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month study was conducted in six European countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa was flexibly up-titrated to a maximum dose of 600 mg/day. Presence of augmentation was diagnosed independently by two international experts using established criteria. In addition to the augmentation severity rating scale (ASRS), changes in RLS severity (International RLS severity rating scale (IRLS), clinical global impression (CGI)) were analyzed. Sixty patients provided evaluable data, 35 completed the trial and 25 dropped out. Augmentation occurred in 60% (36/60) of patients, causing 11.7% (7/60) to drop out. Median time to occurrence of augmentation was 71 days. The mean maximum dose of levodopa was 311 mg/day (SD: 105). Patients with augmentation compared to those without were significantly more likely to be on higher doses of levodopa (> or =300 mg, 83 vs. 54%, P = 0.03) and to show less improvement of symptom severity (IRLS, P = 0.039). Augmentation was common with levodopa, but could be tolerated by most patients during this 6-month trial. Patients should be followed over longer periods to determine if dropout rates increase with time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.